Enhancing personalized care in HR+ early breast cancer: How MGAs help to individualize risk-based systemic treatment decisions

Professor Giampaolo Bianchini is Head of Breast Oncology in the Department of Medical Oncology at IRCCS Ospedale San Raffaele and Associate Professor at Vita-Salute San Raffaele University in Italy. Professor Bianchini manages and treats patients with early-stage and metastatic breast cancer and is internationally recognised as an opinion leader in the field of breast cancer. He has a strong interest in the development of new therapies and immunotherapeutic approaches for the treatment of this disease. Professor Bianchini is also responsible for the translational clinical research and immunotherapy group within the Department of Medical Oncology and is involved in numerous research projects dedicated to women with breast cancer. These research projects are aim to understand the mechanisms of response and resistance to available drugs, identify new therapeutic strategies and define useful biomarkers for improving the personalisation of treatments. Professor Bianchini has authored numerous publications in international journals including Nature, The Lancet, Annals of Oncology, The Lancet Oncology, Journal of Clinical Oncology, Nature Medicine, Nature Reviews Clinical Oncology.

Consultancy fees from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Menarini, MSD, Novartis, Roche, Seagen, and Tethis. Honoraria and/or advisory board fees from AstraZeneca, Daiichi Sankyo, EISAI, Eli Lilly, Exact Sciences, Gilead, Helsinn, Menarini, MSD, Novartis, Pfizer, Roche, and Seagen. Support for attending meetings and/or travel from AstraZeneca, Daiichi Sankyo, Eli Lilly, MSD, Novartis, Pfizer, Roche and Takeda. Institutional funding via a research grant from Gilead.

Professor Shani Paluch-Shimon, MBBS, MSc, is a medical oncologist at the Hadassah University Hospital in Jerusalem, Israel. Her research focuses on young women with breast cancer, hereditary breast cancer and health care disparities among culturally diverse populations in Israel, and she established the first clinical service for young women with breast cancer in Israel. Professor Paluch-Shimon was Chair of the Breast Cancer in Young Women international conference, lead author on guidelines for the treatment of young women with breast cancer, and served three terms as subject editor for breast cancer in the European Society of Oncology (ESMO) clinical practice guidelines committee. She has been lead author on screening and prevention guidelines for women with hereditary breast and ovarian cancer syndrome and is a member of the Advanced Breast Cancer Global Alliance consensus panel. Currently, her research focus is on bridging the healthcare gap for culturally and ethnically disadvantaged groups with breast cancer.

Speakers bureau from AstraZeneca, Exact Sciences/Rhenium, Gilead, Lilly, Medison, MSD, Novartis, Pfizer, and Roche. Honoraria from AstraZeneca, Exact Sciences/Rhenium, Lilly, MSD, Novartis, Pfizer, and Roche. Consultancy fees from AstraZeneca, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Stemline and Summit therapeutics. Travel fees from Roche.

Dr Mattea Reinisch, MD, PhD, is Head of the Breast Unit at the University Medical Center Mannheim in Germany. She is an active member of the adjuvant and neoadjuvant Subboard of the German Breast Group, as well as a member at the European Society of Medical Oncology (ESMO), German Society for Ultrasound in Medicine (DEGUM) and the German Cancer Society (DKG). Among others, she is author of various major publications about male breast cancer and deescalating strategies on the axillary surgery. Dr Reinisch has been principal investigator for more than 20 multicentre Phase 2 and 3 clinical trials. She is working on finding strategies to improve study recruitments into clinical trials in Germany, and is co-founder of the locoregional study network west-go-breast.de. Her research has been acknowledged by national and international committees.

Honoraria and/or consultancy fees from AstraZeneca, Böhringer Ingelheim, Daiichi Sankyo, Gilead, Lilly, MSD, Novartis, OnkowissenTV, Pfizer, Roche, Seagen, Somatex, Streamed Up, Wolters Kluwer and Wiley. Travel support from AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Novartis, Pfizer and Roche.